CMSC 2012: Oral Teriflunomide Not Superior to Interferon in Risk of Treatment FailureJune 3rd 2012
The oral disease-modifying drug under development for the treatment of relapsing-remitting multiple sclerosis, teriflunomide, was not superior to interferon beta-1a in risk of treatment failure.
CMSC 2012: Immune Parameters Normalize Within 4 Months of Natalizumab Cessation in the Treatment of RRMSJune 3rd 2012
In the course of a 24-week cessation of treatment with the humanized monoclonal antibody, natalizumab, in patients with RRMS, pharmacokinetic, pharmacodynamic, and serum immune parameters normalized by 4 months.
CMSC 2012: Ischemic Heart Disease and Myocardial Infarction Occur Less Frequently in Hospital Discharges with Multiple SclerosisJune 3rd 2012
People discharged from the hospital with MS are 30% less likely to have had a myocardial infarction and 58% less likely to have ischemic heart disease.
CMSC 2012: Dimethyl Fumarate Improves Annualized Relapse Rate and Risk of Relapse in Patients With RRMSJune 2nd 2012
Treatment with the investigational oral treatment for relapsing-remitting multiple sclerosis, dimethyl fumarate (aka BG-12), yielded significant reductions in the annualized relapse rate and risk of relapse.
CMSC 2012: Alemtuzumab Efficacy in RRMS Patients Who Relapsed on Prior TherapyJune 2nd 2012
The monoclonal antibody, alemtuzumab, significantly reducesthe number of relapses and the accumulation of disability in patients with relapsing-remitting multiple sclerosis who had relapsed on prior therapy.
CMSC 2012: Fingolimod Significantly Reduces Relapse Rates in MS Patients, Regardless of Duration of or Reasons for Discontinuing Prior TherapyJune 1st 2012
The once-daily oral MS drug, fingolimod, reduces annualized relapse rates in patients who achieved unsatisfactory responses when treated with other disease-modifying therapies or who had been treated for an extended period of time.
CMSC 2012: Dimethyl Fumarate Significantly Improves Number and Volume of Lesions on MRI in Relapsing-Remitting MSJune 1st 2012
Treatment with the investigational oral drug for RRMS, dimethylfumarate (aka BG-12), yielded significant reductions in inflammatory disease activity using MRI outcomes.
CMSC 2012: Teriflunomide-associated Hair Thinning is ManageableMay 31st 2012
In clinical trials, treatment of patients with the oral disease-modifying therapy, teriflunomide, for relapsing forms of multiple sclerosis can result in hair loss/thinning, but this side effect is generally manageable.